piracetam has been researched along with Dyskinesia, Drug-Induced in 16 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-3,4 dihydroxyphenylalanine (levodopa)-induced dyskinesia in Parkinson's disease patients is characterized by a mixture of chorea and dystonia." | 3.72 | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. ( Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A, 2004) |
| "Levodopa-treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover." | 2.76 | Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. ( Konitsiotis, S; Peterson, D; Stathis, P; Tagaris, G, 2011) |
| "Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties." | 2.76 | A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. ( Alty, JE; Goy, AG; Kempster, PA; Raghav, S; Reutens, DC; Wong, KK, 2011) |
| "Piracetam is a potent antioxidant, a cerebral neuroprotector, a neuronal metabolic enhancer, and a brain integrative agent." | 2.73 | Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. ( Bersudsky, Y; Dwolatzky, T; Lerner, V; Libov, I; Miodownik, C, 2007) |
| "Levetiracetam was well tolerated." | 2.73 | Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. ( Baker, CB; Cohen, SJ; Saksa, JR; Tek, C; Woods, SW, 2008) |
| "Treatment with levetiracetam 250 mg orally b." | 1.35 | Treatment of tardive dyskinesia with levetiracetam in a transplant patient. ( Abu-Elmagd, KM; Bond, G; Costa, G; Zivković, SA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ozdemir, O | 1 |
| Baytan, B | 1 |
| Gunes, AM | 1 |
| Okan, M | 1 |
| Chen, PH | 1 |
| Liu, HC | 1 |
| Stathis, P | 1 |
| Konitsiotis, S | 1 |
| Tagaris, G | 1 |
| Peterson, D | 1 |
| Wong, KK | 1 |
| Alty, JE | 1 |
| Goy, AG | 1 |
| Raghav, S | 1 |
| Reutens, DC | 1 |
| Kempster, PA | 1 |
| McGavin, CL | 1 |
| John, V | 1 |
| Musser, WS | 1 |
| Bezard, E | 1 |
| Hill, MP | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Michel, A | 1 |
| Grimée, R | 1 |
| Klitgaard, H | 1 |
| Tousi, B | 1 |
| Subramanian, T | 1 |
| Zesiewicz, TA | 1 |
| Sullivan, KL | 1 |
| Maldonado, JL | 1 |
| Tatum, WO | 1 |
| Hauser, RA | 1 |
| Bona, JR | 1 |
| Libov, I | 1 |
| Miodownik, C | 1 |
| Bersudsky, Y | 1 |
| Dwolatzky, T | 1 |
| Lerner, V | 1 |
| Zivković, SA | 1 |
| Costa, G | 1 |
| Bond, G | 1 |
| Abu-Elmagd, KM | 1 |
| Woods, SW | 1 |
| Saksa, JR | 1 |
| Baker, CB | 1 |
| Cohen, SJ | 1 |
| Tek, C | 1 |
| Kabes, J | 1 |
| Sikora, J | 1 |
| Starý, O | 1 |
| Pisvejc, J | 1 |
| Hanzlícek, L | 1 |
| Yonchev, V | 1 |
| Toreva, D | 1 |
| Margova, L | 1 |
| Yonchev, A | 1 |
| Fehr, C | 1 |
| Dahmen, N | 1 |
| Klawe, C | 1 |
| Eicke, M | 1 |
| Szegedi, A | 1 |
| Chaturvedi, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study[NCT00190008] | Phase 3 | 40 participants | Interventional | 2003-08-31 | Completed | ||
| [NCT00291213] | Phase 3 | 50 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for piracetam and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyski | 2011 |
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Ind | 2011 |
Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Leveti | 2006 |
Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
Topics: Administration, Oral; Adult; Aged; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced | 2007 |
Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Algorithms; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Adminis | 2008 |
[Effectiveness of piracetam in tardive dyskinesia - double-blind cross-over controlled trial with a placebo].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans | 1983 |
10 other studies available for piracetam and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Involuntary movements during vitamin B12 treatment.
Topics: Anticonvulsants; Clonazepam; Dyskinesia, Drug-Induced; Female; Humans; Infant; Male; Piracetam; Seve | 2010 |
Rapid improvement of neuroleptic-induced tardive dyskinesia with levetiracetam in an interictal psychotic patient.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levetiracetam; Mi | 2010 |
Levetiracetam as a treatment for tardive dyskinesia: a case report.
Topics: Adrenergic alpha-Agonists; Anticonvulsants; Antidepressive Agents; Chronic Disease; Clonidine; Depre | 2003 |
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
Topics: Animals; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induc | 2004 |
The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
Treatment of tardive dyskinesia with levetiracetam in a transplant patient.
Topics: Aged; Anticonvulsants; Antiemetics; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Metoclo | 2008 |
The effect of some neurotropic drugs on neuroleptic hypersensitivity of dopamine receptors in the central nervous system.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Corpus Striatum; Cyclophosphamide; Drug Hypersensitivi | 1980 |
Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; | 2001 |
Piracetam for drug-induced dyskinesia.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Dyskinesia, Drug-Induced; Female; Humans; Piracetam; Pyrrol | 1987 |